Table 5

Adverse events with PCSK9is

All patients (N=48)Evolocumab (N=33)Alirocumab 150 mg (N=9)Alirocumab 75 mg (N=6)
Influenza-like symptoms12 (25)10 (30)*1 (11)1 (17)
Fatigue/lethargy10 (21)5 (15)5 (56)0 (0)
Nausea6 (13)4 (12)2 (22)0 (0)
Musculoskeletal pain4 (8)1 (3)3 (33)†0 (0)
Injection-site reaction2 (4)2 (6)0 (0)0 (0)
  • All data are n (%). All symptoms were transient and were reported within the first 3 months of initiation.

  • *Three patients discontinued due to influenza-like symptoms.

  • †Two patients discontinued due to musculoskeletal pain.

  • PCSK9is, proprotein convertase subtilisin/kexin type 9 inhibitors.